Drugs / 4'-thio-2'-deoxycytidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02423057 | May 2015 → Mar 2019 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4'-thio-2'-deoxycytidine | “The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance...” NCT02423057 ↗ |
| Known as | 2'-deoxy-4'-thiocytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1169490 ↗ |
| Known as | NSC-764276 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1169490 ↗ |
| Known as | TdCyd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02423057 ↗ |
| Action | Inhibit | “treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion” NCT02423057 ↗ |
| Modality | Small molecule | “The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd)” NCT02423057 ↗ |
| Route | Oral | “TdCyd will be administered orally” NCT02423057 ↗ |
| Target | DNMT1 | “it engages the active site of DNA methyltransferase I (DNMT1)” NCT02423057 ↗ |